Tran, Duy C <br/><br/>
Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.  [electronic resource] 

 -  JAMA dermatology  01 2017 
 - 92-94 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>2168-6084 
<br/><br/><label>Standard No.: </label>10.1001/jamadermatol.2016.3884  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Carcinoma, Squamous Cell--drug therapy<br/>Cell Death<br/>Disease-Free Survival<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Middle Aged<br/>Nivolumab<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Skin Neoplasms--drug therapy<br/>Time Factors<br/>Treatment Outcome